Complex EVAR in Inflammatory and Infective Abdominal and Thoracoabdominal Aortic Aneurysms
Launched by CEVARII · Apr 20, 2024
Trial Information
Current as of November 13, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
The CEVARII study is an international registry that collects information on how doctors manage two rare and serious aortic problems: inflammatory abdominal aortic aneurysms (IAA) and infective native abdominal or thoracoabdominal aneurysms (INAA). It looks at real-world use of complex endovascular repair, a minimally invasive surgery that uses special grafts, to see how patients do after this treatment. This is an observational study, meaning it just observes and collects data rather than testing a new drug or device. The goal is to understand outcomes and help doctors reach better, evidence-based ways to treat these conditions.
If you are eligible, you would be an adult 18 years or older with a confirmed IAA or INAA who has already been treated with complex endovascular repair at a participating center. People with incomplete medical records, prior grafts, or suspected aorto-enteric fistulas are not eligible. Participation involves collecting information from medical records and following patients for up to about 3 years, with check-ins at 1, 6, 12, 24, and 36 months. The main things the study tracks are whether the graft stays open without more procedures, risks of bowel problems or leaks around the graft, death within 30 days of the procedure, conversion to open surgery, rupture, and infection-related complications, plus how long antibiotics or immune-suppressing medicines are used. The study plans to enroll about 220 people and is currently enrolling by invitation, with an estimated completion around 2026.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients aged ≥ 18 years old with a diagnosis of inflammatory abdominal aortic aneurysm (IAA) or infective native aortic aneurysms (INAA), who have undergone complex endovascular aortic repair (cEVAR) are eligible for inclusion in this study.
- Exclusion Criteria:
- • Suboptimal documentation of clinical, laboratory, and imaging findings
- • Presence of prosthetic material (endograft or open graft material)
- • Prior open or endovascular aortic repair
- • Findings suspicious of secondary aorto-enteric or -bronchial fistulas.
About Cevarii
Cevarii is a pioneering clinical trial sponsor dedicated to advancing innovative healthcare solutions through rigorous research and development. With a focus on enhancing patient outcomes, Cevarii collaborates with healthcare professionals and research institutions to design and implement clinical trials that adhere to the highest ethical and scientific standards. The organization leverages cutting-edge technology and a patient-centric approach to streamline trial processes, ensuring efficiency and integrity while fostering a commitment to transparency and collaboration within the scientific community. Cevarii aims to contribute significantly to the development of transformative therapies that address unmet medical needs.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Aurora, Colorado, United States
Patients applied
Trial Officials
MEL J Sharafuddin, MD
Principal Investigator
Memorial Hospital Central, University of Colorado Healthcare
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported